D.A. Davidson & CO. Has $1.89 Million Stock Position in Organon & Co. (NYSE:OGN)

D.A. Davidson & CO. raised its position in Organon & Co. (NYSE:OGN) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 126,820 shares of the company’s stock after acquiring an additional 4,673 shares during the period. D.A. Davidson & CO.’s holdings in Organon & Co. were worth $1,892,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Truist Financial Corp raised its holdings in Organon & Co. by 57.3% in the 4th quarter. Truist Financial Corp now owns 24,237 shares of the company’s stock valued at $362,000 after acquiring an additional 8,827 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of Organon & Co. by 4.9% in the 4th quarter. CIBC Asset Management Inc now owns 25,523 shares of the company’s stock worth $381,000 after buying an additional 1,184 shares in the last quarter. KLCM Advisors Inc. raised its holdings in shares of Organon & Co. by 1.0% in the 4th quarter. KLCM Advisors Inc. now owns 1,227,649 shares of the company’s stock worth $18,317,000 after buying an additional 11,652 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Organon & Co. by 2.7% in the 4th quarter. Principal Financial Group Inc. now owns 1,248,797 shares of the company’s stock worth $18,632,000 after buying an additional 32,485 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D raised its holdings in shares of Organon & Co. by 42.4% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 143,877 shares of the company’s stock worth $2,147,000 after buying an additional 42,817 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

OGN has been the subject of a number of recent research reports. Morgan Stanley dropped their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Organon & Co. presently has an average rating of “Hold” and an average target price of $20.80.

Organon & Co. Stock Down 1.4 %

NYSE OGN opened at $15.47 on Friday. The firm has a market cap of $3.98 billion, a PE ratio of 4.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. Organon & Co. has a one year low of $13.87 and a one year high of $23.10. The stock’s 50 day simple moving average is $15.36 and its 200 day simple moving average is $17.27. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be given a $0.28 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.24%. Organon & Co.’s payout ratio is 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.